Assessing survival rate of HPV-positive and HPV-negative cervical cancer patients

Cover Page

Cite item

Abstract

Currently, studies highlighting features of emergence, development, clinical score and prognosis for patients with HPV-negative cervical cancer are scarce. However, the data regarding high recurrence rate and mortality in patients with HPV-negative head and neck cancer are demonstrated. Here, cervical canal and exocervical scraping samples collected from 116 patients with primary cervical cancer, I–IV stages, aged 24 to 79 years, were examined with real-time PCR assay for assessing prevalence of 12 high oncogenic risk human papillomavirus (HPV) strains, genotyping and viral load. It was found that 84 (72.4%) and 32 cervical cancer patients (27.6%) were positive and negative, respectively, for high oncogenic risk (HR) HPV strains. Based on these data, patients were further subdivided into two groups: HPV-positive and HPVnegative patient group. Genotyping HPV-positive samples revealed that HPV genotype 16 was found in 67.8% of cases that agrees with data published worldwide. In addition, relapse-free and overall survival (HPV-positive and HPV-negative patients) rate were also evaluated in both groups. It was demonstrated that survival rate was significantly decreased in HPVnegative cervical cancer patients additionally characterized by less favorable prognosis. Moreover, length of relapse-free survival as well as overall survival for HPV-positive vs. HPV-negative patients was 102 vs. 68 months as well as 52 vs. 83 months, respectively. On the other hand, it was demonstrated that recurrence rate, clinical score and progression of cervical cancer directly depend on cancer spread observed at primary medical examination. Of note, the majority of primary cervical cancer relapses are diagnosed within the first 2 years after completing treatment. In addition, an increasing relapse rate has been documented in cervical cancer patients at advanced stages. Upon that, biological cancer behavior remains poorly predictable even in patients at similar disease stage. Therefore, it is essential that HPV as an important prognostic factor would be taken into account for choosing proper therapeutic strategy for treatment of patients with cervical cancer.

About the authors

M. K. Ibragimova

Cancer Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”;
National Research Тomsk State University

Author for correspondence.
Email: imk1805@yandex.ru

Junior Researcher, Laboratory of Oncovirology Cancer Research Institute;

Graduate Student, Department of Human and Animal Physiology Institute of Biology, Ecology, Soil Science of Agriculture and Forestry,

634009, Tomsk, Kooperativnii lane, 5

Russian Federation

M. M. Tsyganov

Cancer Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”

Email: tsyganovmm@yandex.ru

PhD (Biology), Researcher, Laboratory of Oncovirology,

Tomsk

O. N. Churuksaeva

Cancer Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”

Email: churuksaevaon@mail.ru

PhD, MD (Medicine), Senior Researcher, Department of Gynecology, 

Tomsk

L. A. Kolomiets

Cancer Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”;
Siberian State Medical University

Email: kolomietsla@oncology.tomsk.ru

PhD, MD (Medicine), Professor, Head of the Department of Gynecology;

Professor of the Department of Oncology, 

Tomsk 

N. V. Litviakov

Cancer Research Institute “Tomsk National Research Medical Center of the Russian Academy of Sciences”;
National Research Тomsk State University

Email: nvlitv72@yandex.ru

PhD, MD (Biology), Head of the Laboratory of Oncovirology;

Associate Professor, Department of Human and Animal Physiology, Institute of Biology, Ecology, Soil Science of Agriculture and Forestry, 

Tomsk

References

  1. Гуськова Е.А., Неродо Г.А., Гуськова Н.К., Порываев Ю.A., Черникова Н.В. Факторы, влияющие на частоту рецидивирования рака шейки матки // Международный журнал прикладных и фундаментальных исследований. 2015. № 10. С. 87–91.
  2. Коломиец Л.А., Чуруксаева О.Н., Шпилева О.В., Уразова Л.Н., Родичева Н.С. Особенности распространения различных типов вирусов папилломы человека (ВПЧ) у пациенток с цервикальными неоплазиями и раком шейки матки в г. Томске // Сибирский онкологический журнал. 2012. Т. 3, № 51. С. 41–45.
  3. Комарова Л.Е. Современные аспекты цитологического скрининга рака шейки матки: обзор // Опухоли женской репродуктивной системы. 2009. № 3–4. С. 78–82.
  4. Назарова Н.М., Прилепская В.Н., Суламанидзе Л.А., Мзарелуа Г., Бестаева Н. Папилломавирусная инфекция: распространенность, диагностика и лечение (обзор литературы). Лечащий врач. 2013. № 11. С. 15–19.
  5. Уразова Л.Н., Мерзлякова М.К., Никитина Е.Г., Писарева Л.Ф., Коломиец Л.А., Чуруксаева О.Н., Шивит-оол А.А. Сравнительное изучение уровня инфицированности вирусом папилломы человека высокого онкогенного риска женского населения Томской области и Республики Тыва // Эпидемиология и вакцинопрофилактика. 2012. № 6. С. 15–20.
  6. Чуруксаева О.Н., Коломиец Л.А. Онкотропная папилломавирусная инфекция и прогноз течения рака шейки матки // Сибирский онкологический журнал. 2013. № 1. С. 82–87.
  7. Шахтахтинская Ф.Ч., Намазова-Баранова Л.С., Таточенко В.К., Новикова Д.А., Ткаченко Н.Е. Вирус папилломы человека. Профилактика ВПЧ-ассоциированных заболеваний // Педиатрическая фармакология. 2015. Т. 12, № 1. С. 74–78.
  8. Böhmer, G., van den Brule A.J., Brummer O., Meijer C.L., Petry K.U. No confirmed case of human papillomavirus DNAnegative cervical intraepithelial neoplasia grade 3 or invasive primary cancer of the uterine cervix among 511 patients. Am. J. Obstet. Gynecol., 2003, no. 189, pp. 118–120. doi: 10.1067/mob.2003.439
  9. Bosch F.X. Human papillomavirus: science and technologies for the elimination of cervical cancer. Expert Opin. Pharmacother., 2011, no. 12, рр. 2189–2204. doi: 10.1517/14656566.2011.596527
  10. Dahlgren L., Dahlstrand H., Lindquist D., Högmo A., Björnestål L., Lindholm J., Lundberg B., Dalianis T., Munck-Wikland E. Human papillomavirus is more common in base of tongue than in mobile tongue cancer and is a favorable prognostic factor in base of tongue cancer patients. Int. J. Cancer., 2004, no. 112, pp. 1015–1019. doi: 10.1002/ijc.20490
  11. Datta N.R., Kumar P., Singh S., Gupta D., Srivastava A., Dhole T.N. Does pretreatment human papillomavirus (HPV) titers predict radiation response and survival outcomes in cancer cervix? A pilot study. Gynecol. Oncol., 2006, no. 103, pp. 100–105. doi: 10.1016/j.ygyno.2006.01.058
  12. Fakhry C., Westra W.H., Li S., Cmelak A., Ridge J.A., Pinto H., Forastiere A., Gillison M.L. Improved survival of patients with human papillomavirus–positive head and neck squamous cell carcinoma in a prospective clinical trial. J. Natl. Cancer Inst., 2008, no. 100, pp. 261–269. doi: 10.1093/jnci/djn011
  13. Harima Y., Sawada S., Nagata K., Sougawa M., Ohnishi T. Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 2002. no. 52, pp. 1345–1351. doi: 10.1016/S0360-3016(01)02796-1
  14. Lassen P., Eriksen J.G., Hamilton-Dutoit S., Tramm T., Alsner J., Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2009, no. 27, pp. 1992– 1998. doi: 10.1200/JCO.2008.20.2853
  15. Licitra L., Perrone F., Bossi P., Suardi S., Mariani L., Artusi R., Oggionni M., Rossini C., Cantù G., Squadrelli M. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J. Clin. Oncol., 2006, no. 24, pp. 5630–5636. doi: 10.1200/JCO.2005.04.6136
  16. Munoz N., Bosch F.X., de Sanjose S., Herrero R., Castellsagué X., Shah K.V., Snijders P.J., Meijer C.J. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med., 2003, no. 348, pp. 518–527. doi: 10.1056/NEJMoa021641
  17. Sasieni P., Castanon A., Cuzick J. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ, no. 339: b2968. doi: 10.1136/bmj.b2968
  18. Snijders P.J., Verhoef V.M., Arbyn M., Ogilvie G., Minozzi S., Banzi R., van Kemenade F.J., Heideman D.A., Meijer C.J. Highrisk HPV testing on self-sampled versus clinician-collected specimens: a review on the clinical accuracy and impact on population attendance in cervical cancer screening. Int. J. Cancer, 2013, no. 132, pp. 2223–2236. doi: 10.1002/ijc.27790
  19. Steenbergen R.D., Snijders P.J., Heideman D.A., Meijer C.J. Clinical implications of (epi) genetic changes in HPV-induced cervical precancerous lesions. Nat. Rev. Cancer, 2014. no. 14, pp. 395–405. doi: 10.1038/nrc3728

Supplementary files

There are no supplementary files to display.


Copyright (c) 2019 Ibragimova M.K., Tsyganov M.M., Churuksaeva O.N., Kolomiets L.A., Litviakov N.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies